Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

Bibliography

• FERRARA N, GERBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9(6):669-676.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):2335-2342.
   PubMed Web of Science ®Google Scholar
• SANDLER A, GRAY R, PERRY MC et al.: Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. (2006) 355:2542-2550.
   PubMed Web of Science ®Google Scholar
• MILLER KD, WANG M, GRALOW J et al.: A randomized Phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. Proc. Am. Soc. Clin. Oncol. (2005) 23:LBA.
   Google Scholar
• HARARI PM: Epidermal growth factor receptor inhibition strategies in oncology. Endocr. Relat. Cancer (2004) 11(4):689-708.
   PubMed Web of Science ®Google Scholar
• FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2003) 21(12):2237-2246.
   PubMed Web of Science ®Google Scholar
• KRIS MG, NATALE RB, HERBST RS et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA (2003) 290(16):2149-2158.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, RODRIGUES PJ, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353(2):123-132.
   PubMed Web of Science ®Google Scholar
• THATCHER N, CHANG A, PARIKH P et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet (2005) 366(9496):1527-1537.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351(4):337-345.
   PubMed Web of Science ®Google Scholar
• ICHIHARA M, MURAKUMO Y, TAKAHASHI M: RET and neuroendocrine tumors. Cancer Lett. (2004) 204(2):197-211.
   PubMed Web of Science ®Google Scholar
• WEDGE SR, OGILVIE DJ, DUKES M et al.: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. (2002) 62(16):4645-4655.
   PubMed Web of Science ®Google Scholar
• CARLOMAGNO F, VITAGLIANO D, GUIDA T et al.: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. (2002) 62(24):7284-7290.
   PubMed Web of Science ®Google Scholar
• HENNEQUIN LF, STOKES ES, THOMAS AP et al.: Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. (2002) 45(6):1300-1312.
   PubMed Web of Science ®Google Scholar
• RYAN AJ, WEDGE SR: ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br. J. Cancer (2005) 92(Suppl. 1):S6-S13.
   PubMed Web of Science ®Google Scholar
• ARAO T, FUKUMOTO H, TAKEDA M, TAMURA T, SAIJO N, NISHIO K: Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res. (2004) 64(24):9101-9104.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, CAPUTO R, DAMIANO V et al.: Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. (2003) 9(4):1546-1556.
   PubMed Web of Science ®Google Scholar
• CARLOMAGNO F, GUIDA T, ANAGANTI S et al.: Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene (2004) 23(36):6056-6063.
   PubMed Web of Science ®Google Scholar
• TAGUCHI F, KOH Y, KOIZUMI F, TAMURA T, SAIJO N, NISHIO K: Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer Sci. (2004) 95(12):984-989.
   PubMed Web of Science ®Google Scholar
• SHIBUYA K, KOMAKI R, SHINTANI T et al.: Combined blockade of VEGFR and EGFR with ZD6474 enhances the antitumor and antivascular effects of radiation therapy in an orthotopic mouse model of human lung cancer. Proc. Am. Assoc. Cancer Res. (2005) 46:5828 (Abstract).
   Google Scholar
• WILLIAMS KJ, TELFER BA, BRAVE S et al.: ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin. Cancer Res. (2004) 10(24):8587-8593.
   PubMed Web of Science ®Google Scholar
• TUCCILLO C, ROMANO M, TROIANI T et al.: Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin. Cancer Res. (2005) 11(3):1268-1276.
   PubMed Web of Science ®Google Scholar
• HOLDEN SN, ECKHARDT SG, BASSER R et al.: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol. (2005) 16(8):1391-1397.
   PubMed Web of Science ®Google Scholar
• TAMURA T, MINAMI H, YAMADA Y et al.: A Phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J. Thoracic Oncol. (2006) 1:1002-1009.
   PubMed Web of Science ®Google Scholar
• MILLER KD, TRIGO JM, WHEELER C et al.: A multicenter Phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res. (2005) 11(9):3369-3376.
   PubMed Web of Science ®Google Scholar
• KOVACS MJ, REECE DE, MARCELLUS D et al.: A Phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma-NCIC CTG IND.145. Invest. New Drugs (2006) 24(6):529-535.
   PubMed Web of Science ®Google Scholar
• NATALE RB, BODKIN D, GOVINDAN R et al.: ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized Phase II trial. Proc. Am. Soc. Clin. Oncol. (2006):7000 (Abstract).
   Google Scholar
• NAKAGAWA K, KIURA K, SHINKAI T et al.: A randomized double-blind Phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC. Proc. Am. Soc. Clin. Oncol. (2006):7067 (Abstract).
   Google Scholar
• HEYMACH JV, JOHNSON BE, PRAGER D et al.: A Phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results. Proc. Am. Soc. Clin. Oncol. (2006):7016 (Abstract).
   Google Scholar
• JOHNSON BE, MA P, WEST H et al.: Preliminary Phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as first-line treatment in patients with NSCLC. Proc. Am. Soc. Clin. Oncol. (2005):7102 (Abstract).
   Google Scholar
• WELLS S, YOU YN, LAKHANI V et al.: A Phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. Proc. Am. Soc. Clin. Oncol. (2006):5533 (Abstract).
   Web of Science ®Google Scholar
• HEYMACH JV, DONG R-P, DIMERY I et al.: ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: results of the run-in phase of a two-part, randomized Phase II study. Proc. Am. Soc. Clin. Oncol. (2004):3051 (Abstract).
   Google Scholar
• HEYMACH J, WEST H, KERR R et al.: ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: results of the run-in phase of a two-part randomized Phase II study. Lung Cancer (2005) 49(Suppl. 2):S247.
   Google Scholar
• SMITH RP, KENNEDY S, ROBERTSON J, SANDALL D, OLIVER R: The effect of food on the intra-subject variability of the pharmacokinetics of ZD6474, a novel antiangiogenic agent, in healthy subjects. Proc. Am. Soc. Clin. Oncol. (2005):3167 (Abstract).
   PubMed Web of Science ®Google Scholar
• KEEFE DL: The cardiotoxic potential of the 5-HT3 receptor antagonist antiemetics: is there cause for concern? Oncologist (2002) 7(1):65-72.
   PubMed Web of Science ®Google Scholar
• JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22(11):2184-2191.
   PubMed Web of Science ®Google Scholar
• SOCINSKI MA, NOVELLO S, SANCHEZ JM et al.: Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter Phase II trial. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S Part I):7001 (Abstract).
   Google Scholar
• GATZEMEIER U, BLUMENSCHEIN G, FOSELLA F et al.: Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S Part I):7002 (Abstract).
   Google Scholar
• PUTNAM JB Jr: Malignant pleural effusions. Surg. Clin. North Am. (2002) 82(4):867-883.
   PubMed Web of Science ®Google Scholar
• YANO S, HERBST RS, SHINOHARA H et al.: Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin. Cancer Res. (2000) 6(3):957-965.
   PubMed Web of Science ®Google Scholar
• YANO S, SHINOHARA H, HERBST RS et al.: Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am. J. Pathol. (2000) 157(6):1893-1903.
   PubMed Web of Science ®Google Scholar
• ZEBROWSKI BK, YANO S, LIU W et al.: Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res. (1999) 5(11):3364-3368.
   PubMed Web of Science ®Google Scholar
• THICKETT DR, ARMSTRONG L, MILLAR AB: Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax (1999) 54(8):707-710.
   PubMed Web of Science ®Google Scholar
• CHENG D, RODRIGUEZ RM, PERKETT EA et al.: Vascular endothelial growth factor in pleural fluid. Chest (1999) 116(3):760-765.
   PubMed Web of Science ®Google Scholar
• WU W, ISOBE T, ITASAKA S et al.: ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer. Mol. Cancer Ther. (In Press).
   Google Scholar
• HEYMACH JV, NILSSON M, BLUMENSCHEIN G, PAPADIMITRAKOPOULOU V, HERBST R: Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin. Cancer Res. (2006) 12(14 Part 2):4441s-4445s.
   PubMed Web of Science ®Google Scholar
• LEE D, HEYMACH JV: Emerging antiangiogenic agents in lung cancer. Clin Lung Cancer (2006) 7(5):304-308.
   PubMed Web of Science ®Google Scholar
• HERBST RS, JOHNSON DH, MININBERG E et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. (2005) 23(11):2544-2555.
   PubMed Web of Science ®Google Scholar
• JAFRI N, SALGIA R: Biology and novel therapeutics for neuroendocrine tumors of the lung. J. Biol. Regul. Homeost. Agents (2004) 18(3-4):275-290.
   PubMed Web of Science ®Google Scholar
• HERBST RS, GIACCONE G, SCHILLER JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 2. J. Clin. Oncol. (2004) 22(5):785-794.
   PubMed Web of Science ®Google Scholar
• HERBST RS, PRAGER D, HERMANN R et al.: TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. (2005) 23(25):5892-5899.
   PubMed Web of Science ®Google Scholar
• HURWITZ HI, FEHRENBACHER L, HAINSWORTH JD et al.: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. (2005) 23(15):3502-3508.
   PubMed Web of Science ®Google Scholar